Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Generex Biotechnology has reported that Antigen Express, the company's wholly owned immunotherapeutics subsidiary, and the Immune Tolerance Network, a non-profit, government-funded consortium, have signed an agreement aimed at implementing a better diagnostic test for type 1 diabetes.
Subscribe to our email newsletter
The diagnostic test is based on technology being developed by Antigen Express. The technology being developed at Antigen Express allows for more potent and specific activation of immune cells, both after immunization and using blood cells ex vivo, said Generex.
In type 1 diabetes, these cells become aberrantly activated to recognize proteins associated with cells involved in insulin secretion, which ultimately leads to the destruction of these cells. Antigen Express technology allows for the more sensitive detection of these inappropriately activated cells in the blood, according to Generex.